Irritable bowel syndrome (IBS) is a common and well-accepted diagnosis but often imprecisely applied to patients in usual clinical practice.
and pathophysiological disturbances appear to be involved in IBS, but so far no mechanism-based subgroupings to guide specific therapy have been soundly established. Thus, diverse therapeutic approaches coexist and are discretionally prescribed by attending clinicians on the basis of major manifestations (i.e., diarrhea-predominance or constipation-predominance), more or less apparent psychological disturbances, and patient preferences (pharmacological versus dietary or microbiological approaches). In this review, we have attempted to update scientific knowledge about the more relevant disease mechanisms involved and relate this more fundamental basis to the various treatment options available today.
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GENERAL CONSIDERATIONS
In Western countries, irritable bowel syndrome (IBS) is a common medical condition with prevalence figures that hover around 10-15% [1] . Other countries around the world also report high prevalence figures, albeit more variable. IBS also constitutes a substantial fraction of specialist consultations that, in the USA, has been estimated to be close to 20% [2] . IBS impacts considerably on a patient's daily living and quality of life while increasing healthcare resource use and expenditure.
Consequently, IBS results in a substantial financial and economic burden including costs
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for consultations, diagnostic tests, medications, and preventive measures together with substantial productivity losses. IBS is a term that currently enjoys favor with medical professionals and it is also increasingly recognized as a valid diagnosis by patients.
However, the definition and especially the scope of IBS as a medical condition remain somewhat imprecise because its diagnosis is entirely symptom-based and there are no biomarkers or diagnostic technologies available for precise characterization [3, 4] .
Since 1992, there have been four major consecutive attempts at defining IBS by consensus during medical expert meetings in Rome, the last being held in 2015. The successively refined definition of IBS that has emerged from these Rome meetings has been helpful in popularizing the term IBS and providing concrete symptom criteria. In turn, these established criteria have enabled regulatory agencies to standardize the requirements for the performance of randomized control trials, subsequently conducted by pharma industries striving to obtain approval for new drugs intended for treatment of IBS. From the above perspective, the Rome process has yielded generally accepted outcomes and proven value.
However, problems remain with the exclusively symptom-based definition of IBS that risks mixing pathophysiologies and possibly even etiologies within trial study groups. Furthermore, concerns have been expressed about the difficulties that would be encountered in the future to disentangle the current terminology should new methods be developed to establish the diagnosis beyond exclusive symptom criteria. Furthermore, as pointed out by Quigley and Shanahan [5] , an exclusively symptom-based definition of a medical condition such as IBS and other functional syndromes may unintentionally create an illusion of understanding and equate complaints with ''disease''. Such risk is already noticeable in clinical practice as physicians often include cases of unexplained abdominal pain into the IBS diagnosis without specifically checking whether all these patients really meet published Rome criteria [6] .
Another important aspect of IBS diagnosis, which is highly relevant to therapeutic strategies, is the fact that patients with IBS often manifest associated extraintestinal symptoms and comorbid conditions. Among the most common are fatigue, musculoskeletal 
APPROACHING IBS THERAPY FROM A PATHOPHYSIOLOGICAL PERSPECTIVE
Any therapeutic approach to IBS should contemplate the aspects outlined in Table 1, including epidemiological data applicable to an individual patient, the specific symptomatology and severity of illness, the associated manifestations, and comorbidities that may be present, and the personality traits and psychosomatic aspects, which cannot be ignored. These various features may provide useful hints about the pathogenetic mechanisms operating in a given patient, helping us direct the various potential therapeutic measures in the most efficient way. Let us consider next the most relevant aspects of such a discriminating approach.
Immunological Gut Dysregulation
There is mounting evidence of altered gut mucosal immune activity [9] [10] [11] Heightened awareness of the role of gluten sensitivity in the pathogenesis of celiac disease has quickly evolved into the concept of ''gluten intolerance'' portrayed as an IBS-like condition clinically manageable by dietary gluten restriction. This ''gluten-free healthy diet'' concept has rapidly spread to the fashion and media community and from them to the general population where it has acquired many adepts. The marketing of gluten-free food products has rapidly expanded in suit.
Uncertainties as to the pathogenesis of the phenomenon and the actual therapeutic value of gluten avoidance (total or partial) in these individuals are still the subject of controversy.
Prebiotics [40] . The information compiled above leads to the conclusion than abdominal pain, a key feature of IBS, results from a combination of disturbed peripheral pain signaling and disturbed emotional and cognitive pain modulation. As Drossman [41] has pointed out, functional disorders are placed within the range that spans from illness (personal experience of a medical condition) to disease (abnormalities in structure and function of organs and tissues). In a given patient symptom, criteria are insufficient to establish the precise location within the spectrum; however, when the physician carefully takes into consideration the whole clinical picture, the relative weight of central and peripheral mechanisms may be ascertained and help in choosing well among available therapeutic options.
Disturbed Bile Acid Homeostasis
Chronic diarrhea may be induced by excess bile acids in the colon that stimulate motility and mucus production. Bile acid malabsorption may be observed after ileal resection, cholecystectomy, and there is also an idiopathic form induced by bile acid overproduction in the liver [42] . Bile acid malabsorption has been observed in some patients with IBS-D and postulated as a pathogenetic mechanism for their condition [43] [44] [45] .
CURRENT TREATMENT APPROACHES FOR IBS
Taking into consideration the various potential mechanisms involved in the pathogenesis of IBS that we have succinctly reviewed above, one may schematically classify treatment options as shown below and summarized in Table 2 :
• Treatments based on diet modifications.
• Treatments directed towards normalization of microbiome ecology.
• Treatments directed against mucosal inflammation.
• Treatments aiming to normalize intestinal motility.
• Treatments directed to correct disturbances along the brain-gut axis and its regulatory pathways.
• Treatment of colonic bile acid overload.
Diet Modifications
Diet manipulations are a potential therapeutic measure that has been quickly and broadly assumed by the general consumer market without complete understanding of the mechanism of action, criteria for selection of A strict low FODMAP diet is not easy to sustain in the long term, which may account for partial or short-term responses outside controlled trials [50] , but it is not a nutrient-deficient diet and fulfills current nutritional standards. However, a low FODMAP diet affects the gut microbiota and we ignore the potential long-term consequences Many probiotics are commercially available and in fact often tried by patients with IBS with or without professional advice. However, the drawbacks pointed out above remain an obstacle to well-founded medical prescription.
Yet, some aspects of probiotic therapy are particularly appealing, such as the concept of a microbiota-brain-gut axis [60, 61] . Indeed, under certain conditions probiotic bacteria may modulate behavior and brain biochemistry via the vagus nerve [62] and other neural and endocrine pathways. Moreover, prior data suggest that anxiety/depression facilitate gut inflammation [63] and, conversely, Bifidobacterium longum may reduce brain emotional reactivity in IBS [64] . Thus, probiotic-induced changes in the gut microbiota appear to modify gut neuromotor functions. These encouraging laboratory data would support a role for probiotics in the treatment of IBS, but outcomes of clinical studies remain equivocal and sometimes contradictory. As pointed out earlier, the lack of good biomarkers of healthy microbiota to predict disease has slowed down progress in search for appropriate probiotic therapy. Future progress in this field is likely to produce useful advances.
Acting on Gut Mucosal Inflammation
Intestinal inflammation, be it post-infectious, allergic, or idiopathic, is a recognizable feature, especially in IBS-D but also in other IBS subgroups. Some years ago, it was observed that chronic users of steroids were at a reduced risk for developing IBS [65] . Disappointingly, however, additional studies showed that treatment of patients with post-infectious IBS with prednisolone was not clinically efficacious [66] , and two recent trials of mesalazine treatment in IBS yielded negative outcomes Some antidepressants with histamine H 1 receptor affinity tend to produce somnolence and weight gain (i.e., mirtazapine). These properties may be useful to help some patients obtain better sleep and to stimulate their appetite but may be inconvenient to other patients. Side effects of some antidepressants such as sexual dysfunction, arrhythmia, restlessness, and orthostatic hypotension may pose difficulties in some cases and also limit their usefulness. Furthermore, it has been pointed out that side effects tend to be more common and limiting when antidepressants are used for IBS than when used for major depression, perhaps reflecting the peculiarities of functional-type patients. As a rule, off-label treatment of IBS with antidepressants involves much lower doses than for overt psychiatric disorders. However, some patients with IBS are truly affected by anxiety/depression and may benefit from standard doses of these drugs.
Agents that Modify Colonic Fluid and Motor Dynamics
Alosetron, a serotonin 5HT 3 
Bile Acid Sequestrants
Cholestyramine is a nondigestible resin that binds to bile acids in the intestine and prevents their irritating colonic effects while increasing their excretion in feces. Cholestyramine has been widely employed in various diarrheal conditions associated with excess colonic bile acids. It appears to be effective in patients with IBS-D with elevated bile acid excretion [44] .
Cholestyramine is unpalatable, which decreases patient compliance and may induce uncomfortable symptoms on its own such as constipation, flatulence, bloating, and others, but these are usually minor [77] . Colestipol is a somewhat more palatable bile acid sequestrant with similar action. Colesevelam is the latest sequestrant to be developed and it is available in tablet form which increases its acceptability [78] . Bile acid synthesis increases during colesevelam therapy and appears to compensate for increased fecal bile acid loss, hence preventing fat malabsorption in the proximal small bowel [43] . A trial of bile acid sequestrants may be appropriate for patients with IBS-D. 
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